Effects and Underlying Mechanism of Lipid Lowering Intervention on Vascular Protection in Hypertensive Patients
Launched by CHINESE ACADEMY OF MEDICAL SCIENCES, FUWAI HOSPITAL · Sep 29, 2014
Trial Information
Current as of June 06, 2025
Unknown status
Keywords
ClinConnect Summary
EMINENT study is to evaluate the efficacy of Xuezhikang or atorvastatin on vascular function protection in hypertensive patients at low/moderate cardiovascular risk.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients must meet the hypertension with low or moderate cardiovascular risk following 2010 Guidelines for prevention and treatment of hypertension in China
- Exclusion Criteria:
- • Secondary Hypertension
- • Women who are pregnant or lactating
- • History of mental instability, or major psychiatric illness not adequately controlled and stable on therapy
- • Type 2 Diabetes
- • Active liver disease or impaired liver function tests
- • Impaired renal function
- • Uncontrolled cardiac arrhythmia
- • Patient who is unable to give informed consent
- • Any condition or situation, which in the opinion of the investigator, might pose a risk to the patient or confound the results of the study
About Chinese Academy Of Medical Sciences, Fuwai Hospital
The Chinese Academy of Medical Sciences (CAMS) Fuwai Hospital is a leading institution in cardiovascular research and healthcare in China, renowned for its commitment to advancing medical knowledge and improving patient care. As a major clinical trial sponsor, Fuwai Hospital focuses on innovative therapies and interventions, leveraging its extensive resources and expertise in cardiology and related fields. The institution fosters collaboration among multidisciplinary teams of researchers and healthcare professionals, aiming to translate scientific discoveries into clinical applications effectively. With a robust regulatory framework and a dedication to ethical research practices, CAMS Fuwai Hospital plays a pivotal role in addressing critical health challenges and enhancing the quality of life for patients both nationally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Aimin Dang, Doctor
Principal Investigator
Fuwai Hospital & Cardiovascular Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials